Davis Polk advised the joint book-running managers in connection with the SEC-registered offering by Deciphera Pharmaceuticals, Inc. of 10,810,810 shares of common stock for gross proceeds of approximately $400 million. The common stock is listed on the Nasdaq Global Select Market under the symbol “DCPH.”

Headquartered in Waltham, Massachusetts, Deciphera Pharmaceuticals is a clinical-stage biopharmaceutical company focused on addressing key mechanisms of tumor drug resistance that limit the rate and/or durability of response to existing cancer therapies. The company’s pipeline consists of tumor-targeted and immune-targeted drug candidates designed to improve outcomes for patients with cancer by improving the quality, rate and/or durability of their responses to treatment.

The Davis Polk corporate team included partner Richard D. Truesdell Jr., counsel Jeffrey S. Ramsay, and associate Jaryn S. Fields. Partner David R. Bauer, counsel Bonnie Chen and associate Jay Frankel provided intellectual property and technology advice. Partner Mario J. Verdolini and associate Liang Zhang provided tax advice. Counsel David A. Zilberberg provided environmental advice. Counsel Marcie A. Goldstein provided FINRA advice. All members of the Davis Polk team are based in the New York office.

Copy link to share post